Compare EVO & NMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVO | NMM |
|---|---|---|
| Founded | 1993 | 2007 |
| Country | Germany | Greece |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2021 | 2007 |
| Metric | EVO | NMM |
|---|---|---|
| Price | $3.31 | $54.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 99.6K | ★ 122.7K |
| Earning Date | 11-05-2025 | 11-18-2025 |
| Dividend Yield | N/A | ★ 0.37% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 8.94 |
| Revenue | $887,396,457.00 | ★ $1,311,114,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.78 | $9.93 |
| P/E Ratio | ★ N/A | $6.08 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.84 | $28.37 |
| 52 Week High | $5.10 | $54.80 |
| Indicator | EVO | NMM |
|---|---|---|
| Relative Strength Index (RSI) | 49.54 | 74.07 |
| Support Level | $2.89 | $52.52 |
| Resistance Level | $3.24 | $54.12 |
| Average True Range (ATR) | 0.09 | 1.46 |
| MACD | 0.04 | 0.07 |
| Stochastic Oscillator | 95.65 | 89.96 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.